Point72 Asia Singapore Pte. Ltd. Buys 4,627 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Point72 Asia Singapore Pte. Ltd. grew its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 46.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,593 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,627 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Jazz Pharmaceuticals were worth $1,626,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Jazz Pharmaceuticals by 0.8% during the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock worth $1,770,000 after buying an additional 130 shares during the last quarter. Cardinal Capital Management raised its stake in shares of Jazz Pharmaceuticals by 1.9% during the second quarter. Cardinal Capital Management now owns 12,068 shares of the specialty pharmaceutical company’s stock worth $1,288,000 after buying an additional 227 shares during the last quarter. Finally, Waterfront Wealth Inc. raised its stake in shares of Jazz Pharmaceuticals by 2.5% during the second quarter. Waterfront Wealth Inc. now owns 9,411 shares of the specialty pharmaceutical company’s stock worth $1,004,000 after buying an additional 230 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Down 0.9 %

Jazz Pharmaceuticals stock opened at $121.59 on Monday. The stock has a market capitalization of $7.35 billion, a PE ratio of 17.13, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a 50 day moving average of $114.87 and a 200-day moving average of $111.13.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares of the company’s stock, valued at $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,110 shares of company stock valued at $720,160 over the last 90 days. 4.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

JAZZ has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Needham & Company LLC reissued a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Piper Sandler reissued an “overweight” rating and set a $163.00 price target (down from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Cantor Fitzgerald reissued an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Finally, TD Cowen decreased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $175.33.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.